@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastro esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum containing chemotherapy 1 1 in combination with docetaxel for treatment of metastatic non small cell lung cancer with disease progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza 1 2 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 1 3 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 4 ng ml and have been treated with sorafenib 1 4 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with disease progression on or after platinum based chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "NHdqiLdcFb7j9YujwVJrDrMfkUPvXCqcenz4XiQ0UEXXvgHk67/940GvpvzqdPUU5970D3wh6hrbx9v2xzNIDpVmcj5gWGIA7eMNC8+4XEfHsCHs3N04r8Ir1kM+2NeoaNgy5d2HjIw7YReC6IrEkMGkoxDBwfyq3mu/L/lfhsI=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T14:43:26.175+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}